Featured Research

from universities, journals, and other organizations

Multimillion-Dollar AIDS Research Grant Won By Rutgers/CABM Scientist

Date:
August 24, 1999
Source:
Rutgers, The State University Of New Jersey
Summary:
Rutgers chemistry professor Dr. Edward Arnold has won a prestigious National Institutes of Health MERIT Award of more than $3 million for ongoing research on reverse transcriptase, used by the AIDS virus uses to replicate its genetic material. RT is the target molecule for leading-edge, AIDS-fighting drugs such as AZT, DDI, Nevirapine and 3TC.

NEW BRUNSWICK/PISCATAWAY, N.J. -- Dr. Edward Arnold, a resident facultymember of the Center for Advanced Biotechnology and Medicine (CABM) anda professor in Rutgers' department of chemistry, has won a prestigiousNational Institutes of Health (NIH) MERIT Award of more than $3 million.

The funding will extend support of Arnold's continuing research on aprotein called reverse transcriptase (RT) that the AIDS virus uses toreplicate its genetic material. RT is the target molecule forleading-edge, AIDS-fighting drugs such as AZT, DDI, Nevirapine and 3TC.

A limited number of the NIH MERIT (Method to Extend Research in Time)Awards are made to investigators who have demonstrated superiorcompetence and outstanding productivity in their research and are likelyto do so in the future. The awards double the amount and duration of aresearcher's existing grant. Arnold currently has a five-year, $3.4million NIH grant that will now be extended to approximately 10 years ata funding level expected to total in the range of $7 million with theMERIT Award five-year extension.

"One of the great developments in modern biology and life sciences isthe breathtaking ability we now have to reduce a lot of importantbiological phenomena to the atomic level," said Arnold, who is aresident of Belle Mead. "We have been able to do this for a crucialpart of the AIDS virus."

Many times a potent drug will be effective initially against HIV but asa result of the virus' ability to mutate, the drug will no longer work. "The emergence of drug resistance presents a stiff challenge incontrolling an infection like HIV and this is a main focus of ours. Oneof the ideals of the pharmaceutical industry is to be able to develop'irresistible' drugs," said Arnold.

An important application of Arnold's research is in the design anddevelopment of more effective drugs for treating AIDS. For almost 10years, he has collaborated with scientists at Janssen Pharmaceutica, asubsidiary of Johnson & Johnson. Arnold and his group have obtaineddetailed pictures of how potential drug molecules made by chemists atJanssen block the essential machinery of the AIDS virus, and togetherthey have published some of their key results in prominent scientificjournals. Arnold's colleagues at Janssen, under the mentorship of Dr.Paul Janssen, the founder of the company, are using these pictures andother information to try to design new families of molecules with betteractivities.

For the past 12 years, Arnold has also been collaborating on thisproblem with Dr. Stephen Hughes of the NIH National Cancer Institute'sCancer Research and Development Center, which is obtaining biochemicaland genetic characterizations of RT while Arnold's laboratory hasgenerated structures in parallel. "What this does is allow us to havean integrated view of a very complex yet crucial player in a biologicalsystem -- in this case, one of extreme interest and importance since itis part of the AIDS virus," said Arnold.

Another key project in Arnold's laboratory, funded by the same agency atNIH but not covered by the MERIT Award, is concerned with AIDS vaccinedesign and development. Arnold co-directs this project with his wife,Dr. Gail Ferstandig Arnold, a CABM faculty member and a researchprofessor in Rutgers' chemistry department.

The Center for Advanced Biotechnology and Medicine is jointlyadministered by the University of Medicine and Dentistry of New Jerseyand Rutgers, the State University of New Jersey, and is designated bythe New Jersey Commission on Science and Technology as one of thestate's advanced technology centers. Funding is provided by theCommission, Rutgers, UMDNJ, and other public and private sources.

EDITOR'S NOTE: Edward Arnold can be contacted at (732) 235-5323 or bye-mail at . Additional information on Arnoldis available at http://www.cabm.rutgers.edu/lab_descriptions/StructBio.html.


Story Source:

The above story is based on materials provided by Rutgers, The State University Of New Jersey. Note: Materials may be edited for content and length.


Cite This Page:

Rutgers, The State University Of New Jersey. "Multimillion-Dollar AIDS Research Grant Won By Rutgers/CABM Scientist." ScienceDaily. ScienceDaily, 24 August 1999. <www.sciencedaily.com/releases/1999/08/990823085137.htm>.
Rutgers, The State University Of New Jersey. (1999, August 24). Multimillion-Dollar AIDS Research Grant Won By Rutgers/CABM Scientist. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1999/08/990823085137.htm
Rutgers, The State University Of New Jersey. "Multimillion-Dollar AIDS Research Grant Won By Rutgers/CABM Scientist." ScienceDaily. www.sciencedaily.com/releases/1999/08/990823085137.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins